|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/21/22 AIM ImmunoTech Inc. 8-K:1,9 6/16/22 12:1.6M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 32K 2: EX-10.1 Material Contract HTML 251K 3: EX-99.1 Miscellaneous Exhibit HTML 11K 7: R1 Cover HTML 48K 10: XML IDEA XML File -- Filing Summary XML 12K 8: XML XBRL Instance -- form8-k_htm XML 15K 9: EXCEL IDEA Workbook of Financial Reports XLSX 6K 5: EX-101.LAB XBRL Labels -- aim-20220616_lab XML 98K 6: EX-101.PRE XBRL Presentations -- aim-20220616_pre XML 65K 4: EX-101.SCH XBRL Schema -- aim-20220616 XSD 12K 11: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 12: ZIP XBRL Zipped Folder -- 0001493152-22-017273-xbrl Zip 67K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| i Delaware | i 001-27072 | i 52-0845822 | ||
| (state or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
| i 2117 SW Highway 484, i Ocala i FL | i 34473 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: i (352) i 448-7797 /
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| i Common Stock, par value $0.001 per share | i AIM | i NYSE American |
C:
Item 1.01 Entry into a Material Definitive Agreement.
On June 16, 2022, we entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square-foot R&D facility at the New Jersey Bioscience Center (“NJBC”), primarily consisting of two separate laboratory suites. The lease commences on July 1, 2022, and runs through August 31, 2027, but can be extended for an additional five-year period. The initial rent is $156,000 per year and is net of additional rent, primarily related to the building. Net rent increases thereafter. A copy of the lease is filed herewith as Exhibit 10.1. The above description of the lease is qualified in its entirety by the terms of the lease and you are referred to the lease for more detailed information.
On June 21, 2022, we issued a press release regarding the facility. A copy of the press release is furnished herewith as Exhibit 99.1.
Cautionary Statement
This Current Report on Form 8-K and the exhibits filed herewith, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the PSLRA. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 10.1 | June 16, 2022 Lease Agreement with NJEDA. | |
| 99.1 | Press Release Dated June 21, 2022. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AIM IMMUNOTECH INC. | ||
| June 21, 2022 | By: | /s/ Thomas K. Equels |
| Thomas K. Equels, CEO | ||
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 8/31/27 | ||||
| 7/1/22 | S-8 | |||
| Filed on: | 6/21/22 | |||
| For Period end: | 6/16/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA 7/01/22 AIM ImmunoTech Inc. S-8 7/01/22 4:143K M2 Compliance LLC/FA |